摘要
目的探讨CCAAT增强子结合蛋白γ(CEBPG)及肺耐药相关蛋白(LRP)在卵巢癌中的表达及与患者预后的关系。方法选取71例卵巢癌患者作为卵巢癌组,取其卵巢癌组织标本。另外选取49例子宫肌瘤同时行附件切除患者作为对照组,取其正常卵巢组织。观察不同组织中CEBPG及LRP的表达情况,分析卵巢癌患者预后的影响因素。结果卵巢癌组织中CEBPG、LRP阳性表达率均明显高于正常卵巢组织,差异均有统计学意义(P﹤0.01)。随访2年后,71例卵巢癌患者生存55例(77.46%),死亡16例(22.54%)。生存与死亡患者组织学类型、CEBPG表达、LRP表达及淋巴结转移情况比较,差异均有统计学意义(P﹤0.01)。经Logistic回归模型分析得出,组织学类型为浆液性、CEBPG阳性、LRP阳性、有淋巴结转移均为卵巢癌患者预后的独立危险因素(P﹤0.05)。结论CEBPG及LRP在卵巢癌中的表达增高,且与卵巢癌预后有着密切的联系,通过检测其水平可评估卵巢癌患者预后情况。
Objective To investigate the expression of CCAAT enhancer binding protein gamma(CEBPG)and lung resistance protein(LRP)in ovarian cancer and their relationship with prognosis.Method A total of 71 ovarian cancer patients were selected as the ovarian cancer group,and their ovarian cancer tissue specimens were collected.In addition,another 49 patients with uterine fibroids who underwent adnexectomy at the same period were selected as the control group,and their normal ovarian tissues were also selected.The expressions of CEBPG and LRP in different tissues were observed,and the prognostic factors of ovarian cancer patients were further analyzed.Result The positive expression rates of CEBPG and LRP in ovarian cancer tissues were significantly higher than those in normal ovarian tissues,and the differences were statistically significant(P<0.01).After 2 years of follow-up,55(77.46%)of 71 patients survived and 16(22.54%)died.There were significant differences in histological type,CEBPG expression,LRP expression,and lymph node metastasis between survival and dead patients(P<0.01).Logistic regression model analysis presented that the serous histological type,CEBPG positive,LRP positive,and lymph node metastasis were independent risk factors for the prognosis of ovarian cancer patients(P<0.05).Conclusion The expressions of CEBPG and LRP are up-regulation in ovarian cancer,and these indicators are closely related to the prognosis of patients.The detection of these indicators would do great help to evaluate the prognosis of ovarian cancer patients.
作者
赵晓娟
魏珂
董菲
樊雅芝
靳新星
ZHAO Xiaojuan;WEI Ke;DONG Fei;FAN Yazhi;JIN Xinxing(Department of Obstetrics and Gynecology,the First People’s Hospital of Xianyang,Xianyang 712000,Shaanxi,China)
出处
《癌症进展》
2022年第4期387-389,406,共4页
Oncology Progress
